IκB genetic polymorphisms and invasive pneumococcal disease

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 2, 2007, Pages 181-187

  Chapman, Stephen J ^a,b   Khor, Chiea C ^a   Vannberg, Fredrik O ^a   Frodsham, Angela ^a   Walley, Andrew ^a   Maskell, Nicholas A ^b   Davies, Christopher W H ^c   Segal, Shelley ^d   Moore, Catrin E ^d   Gillespie, Stephen H ^e   Denny, Paul ^f   Day, Nicholas P ^g   Crook, Derrick W ^d   Davies, Robert J O ^b   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f MRC MAMMALIAN GENETICS UNIT   (United Kingdom)

^g CHO QUAN HOSPITAL   (Viet Nam)

Author keywords

Genetic polymorphisms; Nuclear factor B; Pneumococcal infection

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B INHIBITOR KINASE 1A; NUCLEAR FACTOR KAPPA B INHIBITOR KINASE 1B; NUCLEAR FACTOR KAPPA B INHIBITOR KINASE 1E; UNCLASSIFIED DRUG; I KAPPA B BETA; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NFKBIE PROTEIN, HUMAN; ONCOPROTEIN;

ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EMPYEMA; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MANTEL HAENSZEL TEST; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS INFECTION; ADULT; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MICROBIOLOGY; PLEURA EMPYEMA;

ADULT; CASE-CONTROL STUDIES; EMPYEMA, PLEURAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; I-KAPPA B PROTEINS; PNEUMOCOCCAL INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS;

EID: 34447294571     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200702-169OC     Document Type: Article

References (46)

1. World Health Organization. Pneumococcal vaccines. Wkly Epidemiol Rec 2003;14:110-119.
2. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004;4:144-154.
3. Cooke GC, Hill AVS. Genetics of susceptibility to human infectious disease. Nat Rev Genet 2001;2:967-977.
4. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17.
5. Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-681.
6. Sabroe I, Read RC, Whyte MKB, Dockrell DH, Vogel SN, Dower SK. Toll-like receptors in health and disease: complex questions remain. J Immunol 2003;171:1630-1635.
7. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003;11:293-302.
8. Tergaonkar V, Correa RG, Ikawa M, Verma IM. Distinct roles of IκB proteins in regulating constitutive NF-κB activity. Nat Cell Biol 2005;7:921-923.
9. Wang XW, Tan NS, Ho B, Ding JL. Evidence for the ancient origin of the NF-κB/IκB cascade: its archaic role in pathogen infection and immunity. Proc Natl Acad Sci USA 2006;103:4204-4209.
10. Schroder NWJ, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005;5:156-164.
11. Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen JT, Schmiegel WH, Griga T. A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis 2004;19:153-156.
12. Mozzato-Chamay N, Corbett EL, Bailey RL, Mabey DCW, Raynes J, Conway DJ. Polymorphisms in the IκB-α promoter region and risk of diseases involving inflammation and fibrosis. Genes Immun 2001;2:153-155.
13. Abdallah A, Sato H, Grutters JC, Veeraraghavan S, Lympany PA, Ruven HJ, van den Bosch JM, Wells AU, du Bois RM, Welsh KI. Inhibitor kappa B-alpha (IΛB-α) promoter polymorphisms in UK and Dutch sarcoidosis. Genes Immun 2003;4:450-454.
14. Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR, Abraham E. Variant IRAK-1 haplotype is associated with increased nuclear factor-κB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 2006;173:1335-1341.
15. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Recognition of gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999;163:1-5.
16. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U, Gobel UB, Weber JR, Schumann RR. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003;278:15587-15594.
17. Knapp S, Wieland CW, van't Veer C, Takeuchi O, Akira S, Florquin S, van der Poll T. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 2004;172:3132-3138.
18. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003;100:1966-1971.
19. Spellerberg B, Rosenow C, Sha W, Tuomanen EI. Pneumococcal cell wall activates NF-κB in human monocytes: aspects distinct from endotoxin. Microb Pathog 1996;20:309-317.
20. Schmeck B, Zahlten J, Moog K, van Laak V, Huber S, Hocke AC, Opitz B, Hoffmann E, Kracht M, Zerrahn J, et al. Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promoter. J Biol Chem 2004;279:53241-53247.
21. Amory-Rivier CF, Mohler J, Bedos JP, Azoulay-Dupuis E, Henin D, Muffat-Joly M, Carbon C, Moine P. Nuclear factor-kappaB activation in mouse lung lavage cells in response to Streptococcus pneumoniae pulmonary infection. Crit Care Med 2000;28:3249-3256.
22. Jones MR, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Lung NF-κB activation and neutrophils recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia. J Immunol 2005;175:7530-7535.
23. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995;80:321-330.
24. Courtois G, Smahi A, Reichenbach J, Doffinger R, Cancrini C, Bonnet M, Puel A, Chable-Bessia C, Yamaoka S, Feinberg J, et al. A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 2003;112:1108-1115.
25. Janssen R, van Wengen A, Hoeve MA, ten Dam M, van der Burg M, van Dongen J, van de Vosse E, van Tol M, Bredius R, Ottenhoff TH, et al. The same IκBα mutation in two related individuals leads to completely different clinical syndromes. J Exp Med 2004;200:559-568.
26. Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, Smarason A, Day NP, McPheat WL, Crook DW, et al.; Oxford Pneumococcal Surveillance Group. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002;359:1569-1573.
27. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, Gabe R, Rees GL, Peto TE, Woodhead MA, et al.; First Multicenter Intrapleural Sepsis Trial. (MIST1) Group. UK controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-874.
28. Chapman SJ, Khor CC, Vannberg FO, Maskell NA, Davies CWH, Hedley EL, Segal S, Moore CE, Knox K, Day NP, et al. PTPN22 and invasive bacterial disease. Nat Genet 2006;38:499-500.
29. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJO. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006;174:817-823.
30. Jurinke C, van den Boom D, Cantor CR, Koster H. The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol 2002;77:57-74.
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
32. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229.
33. Nicodemus KK, Liu W, Chase GA, Tsai Y-Y, Fallin MD. Comparison of type I error for multiple test corrections in large single-nucleotide polymorphism studies using principal components versus haplotype blocking algorithms. BMC Genet 2005;6:S78.
34. Miterski B, Bohringer S, Klein W, Sindern E, Haupts M, Schimrigk S, Epplen JT. Inhibitors in the NF-κB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun 2002;3:211-219.
35. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IκB-NF-κB signalling module: temporal control and selective gene activation. Science 2002;298:1241-1245.
36. Whiteside ST, Epinat J-C, Rice NR, Israel A. I kappa B epsilon, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J 1997;16:1413-1426.
37. Lee S-H, Hannink M. Characterization of the nuclear import and export functions of IκBε. J Biol Chem 2002;277:23358-23366.
38. Nelson DE, Ihekwaba AEC, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, et al. Oscillations in NF-κB signaling control the dynamics of gene expression. Science 2004;306:704-708.
39. Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. IκBε provides negative feedback to control NF-κB oscillations, signaling dynamics, and inflammatory gene expression. J Cell Biol 2006;173:659-664.
40. Werner SL, Barken D, Hoffmann A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 2005;309:1857-1861.
41. Lazzaro BP, Sceurman BK, Clark AG. Genetic basis of natural variation in D. melanogaster antibacterial immunity. Science 2004;303:1873-1876.
42. Christman JW, Sadikot RT, Blackwell TS. The role of nuclear factor-κB in pulmonary diseases. Chest 2000;117:1482-1487.
43. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
44. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger BW, Stern DM, Waldherr R, Saeger HD, et al. Role of NFκB in the mortality of sepsis. J Clin Invest 1997;100:972-985.
45. Abraham E. Alterations in cell signaling in sepsis. Clin Infect Dis 2005;41:S459-S464.
46. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2003;3:17-26.